> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Nyxoah’s U.S. Rollout Delivers €16.1 Million — Nine-Month Loss Stays At €66.7 Million
- URL: https://www.bullished.co/nyxoahs-u-s-rollout-delivers-16-1-million-nine-month-loss-stays-at-66-7-million-7d0471c8/
- Published: 2026-11-06T13:05:57.000Z
- Updated: 2026-11-06T13:05:57.000Z
- Description: Revenue reached €23.2 million, but U.S. commercialization and patent litigation increased selling and administrative costs.
- Author: Matteo Parrino
- Tags: SEC Filings, NYXH, Industry: Healthcare

Nyxoah, which makes medical devices for obstructive sleep apnea, generated €16.1 million in U.S. sales in the first nine months of 2026, bringing total revenue to [€23.2 million](https://www.sec.gov/Archives/edgar/data/1857190/000110465926123352/tm2629001d1%5Fex99-2.htm?ref=bullished.co), versus €4.4 million a year earlier. The company said in its interim report published Thursday that its nine-month net loss was €66.7 million, little changed from €66.6 million, as commercialization and patent-litigation costs increased.

## Genio’s U.S. Sales Engine

The U.S. business began with FDA approval of Genio on August 8, 2025, for a subset of patients with moderate-to-severe sleep apnea. Nyxoah started with early-adopter centers, trained surgeons and supplied systems to hospitals and ambulatory surgery centers.

Genio uses an externally powered implant beneath the chin to stimulate nerves that control the tongue, helping prevent the airway from closing during sleep. The treatment is intended for patients who failed, could not tolerate or refused conventional positive airway pressure therapy.

Markets outside the United States produced €7.1 million in nine-month revenue, including €4.3 million in Germany. Nyxoah also sells in Switzerland, the United Kingdom, the Middle East, the Netherlands, Austria, Spain and Italy.

Third-quarter revenue reached €9.2 million, compared with €2.0 million a year earlier. Management expects further sales expansion mainly in the United States; international growth depends on favorable reimbursement decisions.

## The Cost Of Commercialization

Selling, general and administrative expenses rose 31.4% to €47.0 million for the nine months, from €35.8 million. Nyxoah attributed the increase to U.S. launch spending and intellectual-property litigation; legal fees alone reached €3.089 million, versus €1.219 million.

Inspire Medical sued Nyxoah in the U.S. District Court of Delaware on May 30, 2025, alleging infringement of three patents. Nyxoah brought its own suit alleging infringement of three patents on September 15, 2025\. The court consolidated the cases on May 15, 2026, and discovery is underway.

Research and development expenses fell to €30.1 million from €32.0 million. Lower staffing, manufacturing, outsourced development and clinical-study costs were partly offset by higher consulting costs and depreciation and amortization.

Cost of goods sold increased to €9.2 million from €1.7 million. The nine-month operating loss narrowed to €62.957 million from €64.857 million, while the net negative financial result increased to €2.6 million from €1.6 million, mainly because of convertible-bond accounting charges and interest expenses.

## More Liquidity, More Shares

Cash, cash equivalents and financial assets totaled [€77.0 million](https://www.sec.gov/Archives/edgar/data/1857190/000110465926123352/tm2629001d1%5Fex99-2.htm?ref=bullished.co) at September 30, 2026, against €48.0 million at December 31, 2025\. Nyxoah attributed the increase to a second-quarter equity raise and a second drawdown under its term loan facility.

Operating activities used €59.135 million in cash during the nine months, versus €55.738 million a year earlier. Management believes its liquidity can sustain operations and capital needs for at least 12 months from authorization of the financial statements.

The funding also changed holders’ ownership base: outstanding shares reached 101,840,217 at September 30, compared with 43,026,460 at year-end, following cash share issues, convertible-bond conversions and exercises of restricted share units.

Nyxoah is preparing an FDA application to expand Genio’s use to patients with complete concentric collapse of the airway, after its September 2, 2026 study announcement reported that the main safety and efficacy goals were met. That proposed expansion remains subject to FDA review.

### Sources

- [Form 6-K — Interim financial report | 3](https://www.sec.gov/Archives/edgar/data/1857190/000110465926123352/tm2629001d1%5Fex99-2.htm?ref=bullished.co) — SEC EDGAR
- [Nyxoah Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/11/62957638/nyxoah-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [Nyxoah Publie ses Résultats Financiers et Opérationnels du](https://www.globenewswire.com/news-release/2026/11/05/3397057/0/fr/nyxoah-publie-ses-r%C3%A9sultats-financiers-et-op%C3%A9rationnels-du-troisi%C3%A8me-trimestre-2026.html?ref=bullished.co) — globenewswire.com
- [Nyxoah SA (NYXH) Q3 2026 Earnings Call Highlights: U.S. ...](https://nz.finance.yahoo.com/news/nyxoah-sa-nyxh-q3-2026-052602111.html?ref=bullished.co) — Yahoo Finance
- [Nyxoah SA (NYXH) Reports Q3 Loss, Lags Revenue Estimates](https://nz.finance.yahoo.com/news/nyxoah-sa-nyxh-reports-q3-000019412.html?ref=bullished.co) — Yahoo Finance